UCB, a global biopharmaceutical company, recently announced that it will be presenting new data on generalized myasthenia gravis (gMG) treatments at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in Savannah, Georgia.
The company will showcase 14 abstracts, including one oral presentation, focusing on their gMG treatments, RYSTIGGO® and ZILBRYSQ®. These presentations will highlight the long-term safety and efficacy of these treatments, along with real-world studies on clinical outcomes and patient experience in gMG.
Manuela Maronati, Global Asset Head of Neuroimmunology & Rare at UCB, emphasized the company’s commitment to advancing the understanding and treatment of gMG through innovative research. The presentations will include insights from studies like RAISE-XT and MycarinG, showcasing significant progress in managing gMG.
Key data to be presented includes an oral presentation on global education standards for myasthenia gravis, Phase 3b study results on switching to subcutaneous zilucoplan from IV complement component 5 inhibitors, and data from the RAISE-XT trial for zilucoplan.
Additionally, post hoc analyses from the Phase 3 MycarinG trial for rozanolixizumab will be presented, focusing on the impact of treatment on specific muscle weaknesses, evaluation in older patients, and individualized treatment regimens.
UCB will also host an industry-sponsored therapeutic update session on treatment choices for gMG. Emmanuel Caeymaex, Executive Vice President of Patient Impact at UCB, highlighted the company’s efforts to empower healthcare professionals with knowledge and tools to address the challenges faced by the MG community.
The presentations will cover a range of topics, including the impact of rozanolixizumab treatment on specific outcomes, rozanolixizumab treatment patterns, and needs-driven medical education for healthcare professionals in myasthenia gravis.
For healthcare professionals attending the event, UCB has organized sponsored scientific and therapeutic updates. The company’s focus on advancing the standard of care for gMG underscores its dedication to improving the lives of those living with this condition.
UCB’s commitment to ongoing research and innovation in the field of gMG is evident in the breadth and depth of data being presented at the AANEM and MGFA Scientific Session. The company’s efforts to drive progress in the management of gMG reflect its mission to transform the lives of patients with severe immune system diseases.
